In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cobra Therapeutics Ltd.

Division of Vectura Group PLC

Latest From Cobra Therapeutics Ltd.

Gene Delivery: Looking Past the Skeptics

The criticism of gene therapy has been continual and consistent. But in fact, at least some delivery systems do work. It is true, however, that not all vectors work in all diseases, and the challenge for gene delivery start-ups is figuring out which ones work where.
BioPharmaceutical Business Strategies

Medical Research Council Technology

Britain's Medical Research Council has done a lot over the last decade to develop its technology transfer activities. Almost half of the 16 spin-off companies based on MRC research have appeared in the last two years. One important catalyst for this increase in spin-out activity was the founding in 1998 of a venture capital fund with priority access to companies based on MRC-owned technology, the UK Medical Ventures Fund/MVM Ltd. More recently, the creation of Medical Research Council Technology, bringing together three geographically distinct units involved in technology transfer, has led to a simpler, more efficient structure and better staff retention.
BioPharmaceutical Strategy

Epttco Ltd.

The never-ending search for cancer therapies has led researchers in recent years to consider enzyme-prodrug therapy, a way by which a safe, inactive prodrug is converted into a potent cytotoxic drug at a tumor site by delivery of an activating enzyme. Epttco Ltd. intends to join together several such research efforts.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Vectura Group PLC
  • Senior Management
  • David Bloxham, PhD, CEO
    Richard Moulson, Fin. Dir.
    Peter Harris, MD, Medical & Dev. Dir.
    David Thatcher, PhD, Dir., Mftg. Operations
    Andrew Mountain, PhD, Dir., Research
    John Wynne, Dir., Bus. Dev.
  • Contact Info
  • Cobra Therapeutics Ltd.
    Phone: (44) 1782714181
    The Science Park
    Keele, ST5 5SP
    UK
UsernamePublicRestriction

Register